# Moderna, Inc. (MRNA) FY2025 Annual Balance Sheet

- Company: Moderna, Inc. (MRNA)
- Period: As of 2025-12-31
- Filing: FY2025 10-K, filed 2026-02-20, accession number 0001682852-26-000033
- Page: https://plicit.ai/financials/mrna/fy2025-annual-balance-sheet
- Chart image: https://plicit.ai/charts/mrna-fy2025-annual-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2025-12-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 12,338,000,000 US dollars
- **Current assets**: 6,544,000,000 US dollars
- **Non-current assets**: 5,794,000,000 US dollars
- **Liabilities**: 3,688,000,000 US dollars
- **Current liabilities**: 1,987,000,000 US dollars
- **Non-current liabilities**: 1,701,000,000 US dollars
- **Equity**: 8,650,000,000 US dollars
- **Investments**: 3,204,000,000 US dollars
- **Cash and cash equivalents**: 2,595,000,000 US dollars
- **Prepaid expenses and other current assets**: 408,000,000 US dollars
- **Accounts receivable, net**: 184,000,000 US dollars
- **Inventory**: 153,000,000 US dollars
- **Investments, non-current**: 2,336,000,000 US dollars
- **Property, plant and equipment, net**: 2,134,000,000 US dollars
- **Right-of-use assets, operating leases**: 719,000,000 US dollars
- **Other non-current assets**: 605,000,000 US dollars
- **Accrued liabilities**: 1,386,000,000 US dollars
- **Accounts payable**: 317,000,000 US dollars
- **Other current liabilities**: 185,000,000 US dollars
- **Deferred revenue**: 99,000,000 US dollars
- **Operating lease liabilities, non-current**: 653,000,000 US dollars
- **Long-term debt**: 590,000,000 US dollars
- **Other non-current liabilities**: 285,000,000 US dollars
- **Deferred revenue, non-current**: 153,000,000 US dollars
- **Financing lease liabilities, non-current**: 20,000,000 US dollars
- **Retained earnings**: 7,223,000,000 US dollars
- **Additional paid-in capital**: 1,382,000,000 US dollars
- **Accumulated other comprehensive income (loss)**: 45,000,000 US dollars
- **Preferred stock, $0.0001; 162 shares authorized as of December 31, 2025 and 2024; no shares issued or outstanding at December 31, 2025 and 2024**: 0 US dollars
- **Common stock, par value $0.0001; 1,600 shares authorized as of December 31, 2025 and 2024; 394 and 386 shares issued and outstanding as of December 31, 2025 and 2024, respectively**: 0 US dollars

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.